These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10378261)

  • 1. Comparing treatment variances in repeated measures bioavailability trials.
    Jiang G; Sarkar SK
    Stat Med; 1999 May; 18(9):1133-49. PubMed ID: 10378261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of outlying data in bioavailability/bioequivalence studies.
    Liu JP; Weng CS
    Stat Med; 1991 Sep; 10(9):1375-89. PubMed ID: 1925168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.
    Gaudreault J; Potvin D; Lavigne J; Lalonde RL
    Pharm Res; 1998 Oct; 15(10):1621-9. PubMed ID: 9794507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Approach to Testing for Average Bioequivalence Based on Modeling the Within-Period Dependence Structure.
    Chandrasekhar R; Shi Y; Hutson AD; Wilding GE
    J Biopharm Stat; 2015; 25(6):1320-38. PubMed ID: 25671781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
    Liao JJ
    Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Different Sampling Schedules on Results of Bioavailability and Bioequivalence Studies: Evaluation by Means of Monte Carlo Simulations.
    Kano EK; Chiann C; Fukuda K; Porta V
    Drug Res (Stuttg); 2017 Aug; 67(8):451-457. PubMed ID: 28561232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.
    el-Tahtawy AA; Tozer TN; Harrison F; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):98-104. PubMed ID: 9487554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining outlying subjects and outlying records in bioequivalence trials.
    Wang W; Chow SC
    J Biopharm Stat; 2003 Feb; 13(1):43-56. PubMed ID: 12635902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approach to assess bioequivalence parameters using generalized gamma mixed-effect model (model-based asymptotic bioequivalence test).
    Chen YI; Huang CS
    Stat Med; 2014 Feb; 33(5):786-97. PubMed ID: 24105871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of multiple-dose bioequivalence studies.
    Chinchilli VM; Esinhart JD; Barr WH
    J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference of bioequivalence for log-normal distributed data with unspecified variances.
    Xu S; Hua SY; Menton R; Barker K; Menon S; D'Agostino RB
    Stat Med; 2014 Jul; 33(17):2924-38. PubMed ID: 24403216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach for outliers in a bioavailability/bioequivalence study.
    Liao JJ
    J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.